YO-2 | CAS#288254-44-4 | plasmin inhibitor

MedKoo Cat#: 465001 | Name: YO-2

Description:

WARNING: This product is for research use only, not for human or veterinary use.

YO-2 is a selective plasmin inhibitor. YO-2 induces thymocyte apoptosis via activation of caspase cascade.

Chemical Structure

YO-2

CAS#288254-44-4 (free base)

Theoretical Analysis

MedKoo Cat#: 465001

Name: YO-2

CAS#: 288254-44-4 (free base)

Chemical Formula: C31H46N4O3

Exact Mass: 522.3570

Molecular Weight: 522.73

Elemental Analysis: C, 71.23; H, 8.87; N, 10.72; O, 9.18

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

325463-91-0 (HCl) 288254-44-4 (free base)

Synonym

YO-2; YO 2; YO2;

IUPAC/Chemical Name

(1r,4S)-4-(aminomethyl)-N-((S)-1-(octylamino)-1-oxo-3-(4-(pyridin-4-ylmethoxy)phenyl)propan-2-yl)cyclohexane-1-carboxamide

InChi Key

ZBCXDUNUUKRQSV-RWPDHJIBSA-N

InChi Code

InChI=1S/C31H46N4O3/c1-2-3-4-5-6-7-18-34-31(37)29(35-30(36)27-12-8-25(22-32)9-13-27)21-24-10-14-28(15-11-24)38-23-26-16-19-33-20-17-26/h10-11,14-17,19-20,25,27,29H,2-9,12-13,18,21-23,32H2,1H3,(H,34,37)(H,35,36)/t25-,27-,29-/m0/s1

SMILES Code

CCCCCCCCNC([C@@H](NC([C@@H]1CC[C@H](CC1)CN)=O)CC2=CC=C(C=C2)OCC3=CC=NC=C3)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 522.73 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Schlottmann F, Strassle PD, Nayyar A, Herbella FAM, Cairns BA, Patti MG. Postoperative outcomes of esophagectomy for cancer in elderly patients. J Surg Res. 2018 Sep;229:9-14. doi: 10.1016/j.jss.2018.03.050. Epub 2018 Apr 16. PubMed PMID: 29937021. 2: Eiamboonsert S, Salama Y, Watarai H, Dhahri D, Tsuda Y, Okada Y, Hattori K, Heissig B. The role of plasmin in the pathogenesis of murine multiple myeloma. Biochem Biophys Res Commun. 2017 Jun 24;488(2):387-392. doi: 10.1016/j.bbrc.2017.05.062. Epub 2017 May 10. PubMed PMID: 28501622. 3: Cembrowski GS, Xu Q, Cembrowski AR, Mei J, Sadrzadeh H. Impaired clinical utility of sequential patient GEM blood gas measurements associated with calibration schedule. Clin Biochem. 2017 Nov;50(16-17):936-941. doi: 10.1016/j.clinbiochem.2017.03.014. Epub 2017 Mar 18. PubMed PMID: 28322757. 4: Ciodaro F, Cammaroto G, Galletti B, Galletti F. Subannular T-tubes for the treatment of adhesive otitis: how we do it. B-ENT. 2016 Aug;12(2):131-135. PubMed PMID: 29553618. 5: Hidaka K, Gohda K, Teno N, Wanaka K, Tsuda Y. Active site-directed plasmin inhibitors: Extension on the P2 residue. Bioorg Med Chem. 2016 Feb 15;24(4):545-53. doi: 10.1016/j.bmc.2015.12.009. Epub 2015 Dec 8. PubMed PMID: 26732532. 6: Xu Y, Furutani S, Ihara M, Ling Y, Yang X, Kai K, Hayashi H, Matsuda K. Meroterpenoid Chrodrimanins Are Selective and Potent Blockers of Insect GABA-Gated Chloride Channels. PLoS One. 2015 Apr 22;10(4):e0122629. doi: 10.1371/journal.pone.0122629. eCollection 2015. PubMed PMID: 25902139; PubMed Central PMCID: PMC4406737. 7: Munakata S, Tashiro Y, Nishida C, Sato A, Komiyama H, Shimazu H, Dhahri D, Salama Y, Eiamboonsert S, Takeda K, Yagita H, Tsuda Y, Okada Y, Nakauchi H, Sakamoto K, Heissig B, Hattori K. Inhibition of plasmin protects against colitis in mice by suppressing matrix metalloproteinase 9-mediated cytokine release from myeloid cells. Gastroenterology. 2015 Mar;148(3):565-578.e4. doi: 10.1053/j.gastro.2014.12.001. Epub 2014 Dec 6. PubMed PMID: 25490065. 8: Al-Horani RA, Desai UR. Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders. Med Res Rev. 2014 Nov;34(6):1168-216. doi: 10.1002/med.21315. Epub 2014 Mar 21. Review. PubMed PMID: 24659483. 9: Saraya A, Mahavihakanont A, Shuangshoti S, Sittidetboripat N, Deesudchit T, Callahan M, Wacharapluesadee S, Wilde H, Hemachudha T. Autoimmune causes of encephalitis syndrome in Thailand: prospective study of 103 patients. BMC Neurol. 2013 Oct 20;13:150. doi: 10.1186/1471-2377-13-150. PubMed PMID: 24139084; PubMed Central PMCID: PMC3853593. 10: Hayashi H, Oka Y, Kai K, Akiyama K. New chrodrimanin congeners, chrodrimanins D-H, from YO-2 of Talaromyces sp. Biosci Biotechnol Biochem. 2012;76(9):1765-8. Epub 2012 Sep 7. PubMed PMID: 22972343. 11: Hayashi H, Oka Y, Kai K, Akiyama K. A new meroterpenoid, chrodrimanin C, from YO-2 of Talaromyces sp. Biosci Biotechnol Biochem. 2012;76(4):745-8. Epub 2012 Apr 7. PubMed PMID: 22484942. 12: Gohda K, Teno N, Wanaka K, Tsuda Y. Predicting subsite interactions of plasmin with substrates and inhibitors through computational docking analysis. J Enzyme Inhib Med Chem. 2012 Aug;27(4):571-7. doi: 10.3109/14756366.2011.603129. Epub 2011 Oct 12. PubMed PMID: 21992704. 13: Okada Y. [Overview in 45 years of studies on peptide chemistry]. Yakugaku Zasshi. 2009 Oct;129(10):1141-54. Review. Japanese. PubMed PMID: 19797870. 14: Enomoto R, Sugahara C, Tsuda Y, Okada Y, Lee E. Thymocyte apoptosis induced by various compounds including YO-2 is accompanied by a change in chromatin structure. Ann N Y Acad Sci. 2004 Dec;1030:622-6. PubMed PMID: 15659845. 15: Enomoto R, Sugahara C, Komai T, Suzuki C, Kinoshita N, Hosoda A, Yoshikawa A, Tsuda Y, Okada Y, Lee E. The structure-activity relationship of various YO compounds, novel plasmin inhibitors, in the apoptosis induction. Biochim Biophys Acta. 2004 Nov 1;1674(3):291-8. PubMed PMID: 15541298. 16: Szende B, Okada Y, Tsuda Y, Horvath A, Bökönyi G, Okamoto S, Wanaka K, Kéri G. A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number. In Vivo. 2002 Sep-Oct;16(5):281-6. PubMed PMID: 12494864. 17: Lee E, Enomoto R, Takemura K, Tsuda Y, Okada Y. A selective plasmin inhibitor, trans-aminomethylcyclohexanecarbonyl-L-(O-picolyl)tyrosine-octylamide (YO-2), induces thymocyte apoptosis. Biochem Pharmacol. 2002 Apr 1;63(7):1315-23. PubMed PMID: 11960608. 18: Okada Y, Tsuda Y, Wanaka K, Tada M, Okamoto U, Okamoto S, Hijikata-Okunomiya A, Bokonyi G, Szende B, Keri G. Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and HT29 cell lines. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2217-21. PubMed PMID: 11012033. 19: Yonei T, Watarai S, Okada Y, Yasuda T, Tsuji T. Increased urinary excretion of non-albumin antigen detected with YO-2, a novel monoclonal antibody, in diabetic patients. Acta Med Okayama. 1995 Jun;49(3):153-9. PubMed PMID: 7676846. 20: Johnson JA, Hayward JJ, Kornguth SE, Siegel FL. Effects of hyperbilirubinaemia on glutathione S-transferase isoenzymes in cerebellar cortex of the Gunn rat. Biochem J. 1993 Apr 15;291 ( Pt 2):453-61. PubMed PMID: 8484726; PubMed Central PMCID: PMC1132547.